ixazomib proteasome inhibitor
"
Ixazomib Sitrat (1201902-80-8)
Ixazomib Citrate (1201902-80-8) Ixazomib citrate is a proteasome inhibitor that prevents cell growth in solid tumours. This anti-cancer agent is specifically used for the treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate demonstrates superior pharmacokinetics, efficacy, and anticancer activity. Key Features Proteasome inhibitor for cancer treatment Specifically indicated for multiple myeloma Superior pharmacokinetics compared to bortezomib Enhanced
(αR) - ((1S,2S,3R,5S) -Pinanediol-1-amino-3-metilbutan-1-boronat trifluorasetat (179324-87-9)
(αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) is a specialized chemical compound used in the design and preparation of pharmaceutical agents including Ixazomib and Bortezomib. Product Specifications Product Name: (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate CAS No.: 179324-87-9 Assay: 98% End Use:
